MENVEO Israel - inglês - Ministry of Health

menveo

glaxo smith kline (israel) ltd - meningococcal vaccines group a; meningococcal vaccines group c; meningococcal vaccines group w; meningococcal vaccines group y - powder and solution for solution for injection - meningococcal vaccines group y 5 mcg / 0.5 ml; meningococcal vaccines group w 5 mcg / 0.5 ml; meningococcal vaccines group c 5 mcg / 0.5 ml; meningococcal vaccines group a 10 mcg / 0.5 ml - other meningococcal monovalent purified polysaccharides antigen - other meningococcal monovalent purified polysaccharides antigen - menveo is indicated for active immunization of children (2 years of age and above), adolescents and adults up to the age of 55 years, at risk of exposure to neisseria meningitidis groups a, c, w135 and y, to prevent invasive disease. the use of this vaccine should be in accordance with official recommendations.

Nimenrix União Europeia - inglês - EMA (European Medicines Agency)

nimenrix

pfizer europe ma eeig - neisseria meningitidis group a polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group c polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group w-135 polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group y polysaccharide conjugated to tetanus toxoid - meningitis, meningococcal - vaccines - nimenrix is indicated for active immunisation of individuals from the age of 6 weeks against invasive meningococcal diseases caused by neisseria meningitidis group a, c, w-135, and y.

Trumenba União Europeia - inglês - EMA (European Medicines Agency)

trumenba

pfizer europe ma eeig - neisseria meningitidis serogroup b fhbp (recombinant lipidated fhbp (factor h binding protein)) subfamily a; neisseria meningitidis serogroup b fhbp (recombinant lipidated fhbp (factor h binding protein)) subfamily b - meningitis, meningococcal - bacterial vaccines, meningococcal vaccines - trumenba is indicated for active immunisation of individuals 10 years and older to prevent invasive meningococcal disease caused by neisseria meningitidis serogroup b.the use of this vaccine should be in accordance with official recommendations.

NIMENRIX meningococcal (Groups A, C, W-135, Y) polysaccharide tetanus toxoid conjugate vaccine injection vial and diluent ampoul Austrália - inglês - Department of Health (Therapeutic Goods Administration)

nimenrix meningococcal (groups a, c, w-135, y) polysaccharide tetanus toxoid conjugate vaccine injection vial and diluent ampoul

pfizer australia pty ltd - meningococcal polysaccharide group a,meningococcal polysaccharide group c,meningococcal polysaccharide group w135,meningococcal polysaccharide group y,tetanus toxoid -

MENINGITEC SUSPENSION Canadá - inglês - Health Canada

meningitec suspension

nuron biotech b.v. - meningococcal group c oligosaccharide; corynebacterium diphtheriae crm-197 protein - suspension - 10mcg; 15mcg - meningococcal group c oligosaccharide 10mcg; corynebacterium diphtheriae crm-197 protein 15mcg - vaccines

MENJUGATE 10micrograms suspension for injection in vials Reino Unido - inglês - myHealthbox

menjugate 10micrograms suspension for injection in vials

novartis vaccines and diagnostics - neisseria meningitidis group c (strain c11) oligosaccharide, corynebacterium diphtheriae crm197 protein , adsorbed on aluminium - suspension for injection - 10micrograms, 12.5 to 25.0micrograms, 0.3 to 0.4mg al 3+ - meningococcal vaccines - active immunisation of children from 2 months of age, adolescents and adults, for the prevention of invasive disease caused by neisseria meningitidis group c.

MENJUGATE 10micrograms suspension for injection, syringes Reino Unido - inglês - myHealthbox

menjugate 10micrograms suspension for injection, syringes

novartis vaccines and diagnostics - neisseria meningitidis group c (strain c11) oligosaccharide, corynebacterium diphtheriae crm197 protein , adsorbed on aluminium - suspension for injection - 10micrograms, 12.5 to 25.0micrograms, 0.3 to 0.4mg al 3+ - meningococcal vaccines - active immunisation of children from 2 months of age, adolescents and adults, for the prevention of invasive disease caused by neisseria meningitidis group c.

Neisseria IVDs Austrália - inglês - Department of Health (Therapeutic Goods Administration)

neisseria ivds

hologic (australia & new zealand) pty ltd - ct793 - neisseria ivds - the aptima neisseria gonorrhoeae assay is a target amplification nucleic acid probe test that utilizes target capture for the in vitro qualitative detection of ribosomal rna (rrna) from neisseria gonorrhoeae (gc) to aid in the diagnosis of gonococcal urogenital disease

Neisseria IVDs Austrália - inglês - Department of Health (Therapeutic Goods Administration)

neisseria ivds

becton dickinson pty ltd - ct793 - neisseria ivds - an in vitro diagnostic test intended for testing of neisseria gonorrhoeae (gc).

Neisseria IVDs Austrália - inglês - Department of Health (Therapeutic Goods Administration)

neisseria ivds

becton dickinson pty ltd - ct793 - neisseria ivds - ivds that are used for the qualitative detection of neisseria bacteria in clinical specimens.